Vivanza Biosciences Ltd

Vivanza Biosciences Limited will hold a board meeting on August 17, 2026, at its registered office to approve the Director's Report and Secretarial Audit Report for the financial year 2025-26, convene the 44th Annual General Meeting (AGM), appoint Mr. Chintan K. Patel as Scrutinizer for the e-voting and poll process, fix September 04, 2026, as the cut-off date for the AGM, and seek approval for the adoption of the Memorandum of Association and Articles of Association, proposed borrowings under Section 180(1)(c) of the Companies Act, 2013, and proposed transactions under Section 185 of the Companies Act, 2013, as applicable, along with proposed investments, loans, guarantees and/or securities under Section 186 of the Companies Act, 2013.

Vivanza Biosciences Limited informed the BSE Limited on August 8, 2026, that the company has not raised any further funds through a public issue, rights issue, or preferential issue, and therefore, the statement of deviation or variation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable.

Vivanza Biosciences Ltd share price declined by 0.53% to Rs 1.89 after the company's net profit plunged by 133.33% to Rs 0.15 crore, while revenue from operations increased sharply by 46.07% to Rs 9.29 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, rising 5.32%. It has marginally improved by 0.53% over last one week and rose by 11.64% in last one month while the market capitalization of Vivanza Biosciences Ltd has inched up 2.72% and 0.53% in the same period respectively. Profit before tax (PBT) of Vivanza Biosciences Ltd stood at Rs 0.18 crore in Q2 FY26, rallying 100.00% year-on-year, and plunging by 160.00% quarter-on-quarter. EBITDA came in at Rs 0 crore, crashing by 438.46% YoY and expanding by 83.33% sequentially. Total expenses jumped by 41.75% to Rs 9.37 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 0.1 crore, witnessing a strong rise of 42.86% YoY. For the TTM ended FY26, revenue from operations slumped by 73.35% to Rs 7.42 crore, while net profit tanked by 221.82% to Rs 0.67 crore, compared to previous TTM. EBITDA marginally improved 1% to Rs 0.43 crore, and PBT tumbled by 195.71% to Rs 0.67 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.5 crore in FY26, as against Rs 2.04 crore in FY25. Vivanza Biosciences Ltd nosedived by 9.57% in last one year, underperforming the benchmark BSE Sensex which has eased by 1.97% during the same period.

Vivanza Biosciences Limited informed the BSE Limited that a meeting of the Board of Directors has been rescheduled to Friday, August 07th, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a limited review report, and to address other matters including a notice of disclosure of interest and declarations from independent directors.

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 1 August 2026.

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 18 June 2026.

Net Loss of Vivanza Biosciences reported to Rs 0.45 crore in the quarter ended March 2026 as against net loss of Rs 1.00 crore during the previous quarter ended March 2025. Sales rose 1225.00% to Rs 6.36 crore in the quarter ended March 2026 as against Rs 0.48 crore during the previous quarter ended March 2025. For the full year,net profit reported to Rs 0.39 crore in the year ended March 2026 as against net loss of Rs 0.67 crore during the previous year ended March 2025. Sales rose 1462.13% to Rs 115.91 crore in the year ended March 2026 as against Rs 7.42 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales6.360.48 1225 115.917.42 1462 OPM %-3.62-200.00 -0.63-4.85 - PBDT-0.29-0.99 71 0.57-0.65 LP PBT-0.30-0.99 70 0.54-0.67 LP NP-0.45-1.00 55 0.39-0.67 LP Powered by Capital Market - Live

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 4 May 2026.

Net profit of Vivanza Biosciences rose 400.00% to Rs 0.20 crore in the quarter ended December 2025 as against Rs 0.04 crore during the previous quarter ended December 2024. Sales rose 2916.67% to Rs 45.25 crore in the quarter ended December 2025 as against Rs 1.50 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales45.251.50 2917 OPM %0.468.00 - PBDT0.200.05 300 PBT0.200.04 400 NP0.200.04 400 Powered by Capital Market - Live

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live